A new guideline for treating breast cancer patients with whole breast irradiation recommends that most patients receive an accelerated treatment, known as hypofractioned therapy, instead of the conventional one. This means that patients will receive larger doses of radiation delivered across fewer treatment sessions, completing treatment in three to four weeks, instead of the five to seven weeks that conventional therapy requires. Patients will have “more time with family, less time away from work and lower treatment costs” Reshma Jagsi, MD, said in a press release. Jagsi is co-chair of the task force that compiled the guideline and a professor of radiation oncology at the University of Michigan in Ann Arbor. The guideline, "Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline," was developed by the American Society for Radiation Oncology (ASTRO), and published in the journal Practical Radiation Oncology. Whole breast irradiation (WBI) is the most frequently used type of radiation for treating tumors in the breast. With the approach known as hypofractionated WBI, patients are given larger doses of radiation in fewer treatment sessions.